Synthetic studies on myriocin and related natural products using Rh(Ⅱ)-catalyzed C-H amination followed by alkylation by 野田 成美
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㢮⦕యࡢ୰࡛ᵓ㐀ⓗ࡟ࡼࡃఝࡓ myriocin 㢮࡟╔┠ࡋࡓࠋMyriocin (1)㸪mycestericin D 
(2)㸪sphingofungin E (3)ࡣ㸪ࢫࣇ࢕ࣥࢦࢩࣥࡢ C2 ఩ࡢⅣ⣲࡟࢝ࣝ࣎࢟ࢩᇶࡀ⤖ྜࡋ
ࡓ㢮⦕య࡛࠶ࡾ㸪ࡇࡢᅄ⨨᥮୙ᩧⅣ⣲ࢆྵࡴ㐃⥆ࡍࡿ୙ᩧ୰ᚰࢆ᭷ࡍࡿࡇ࡜ࡀᵓ㐀
ୖࡢ≉ᚩ࡛࠶ࡿ (Fig. 1)ࠋMyriocin (1)ࡣ㸪1972 ᖺ㸪Myriococcum albomyces3)࠾ࡼࡧ
Mycelia sterilia4)࠿ࡽ༢㞳ࡉࢀࡓࠋࡉࡽ࡟㸪1994 ᖺ࡟ Isalia sinclairii5)࠿ࡽ༢㞳ࡉࢀࡓ
ISP-1 ࡜ᵓ㐀ࡀྠ୍࡛࠶ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡾ㸪෌ࡧὀ┠ࢆ㞟ࡵࡓࠋMycestericin D (2)
ࡣ㸪 1994 ᖺ࡟ M. sterilia ATCC 203496)࠿ࡽ㸪 sphingofungin E (3)ࡣ㸪 1992 ᖺ㸪
Paecilomyces variotii7㸧ࡼࡾࡑࢀࡒࢀ༢㞳ࡉࢀࡓࠋ1 ࠾ࡼࡧ 2 ࡣ㸪ච␿ᢚไస⏝ࢆ᭷ࡍ
ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗ࡚࠾ࡾ㸪≉࡟ 1 ࡣ㸪ࢩࢡࣟࢫ࣏ࣜࣥ A ࡢ 10 ಸ࠿ࡽ 100 ಸ࡜࠸
࠺ࡁࢃࡵ࡚㧗࠸ච␿ᢚไస⏝ࢆ♧ࡍࠋࡲࡓ㸪1 ࠾ࡼࡧ 3 ࡣ㸪ࢫࣇ࢕ࣥࢦ⬡㉁⏕ྜᡂ࡟
࠾ࡅࡿ㔜せ࡞㓝⣲࡛࠶ࡿ㸪ࢭࣜࣥ-ࣃ࣑ࣝࢺ࢖ࣝ㌿⛣㓝⣲㜼ᐖάᛶࢆ᭷ࡍࡿࡇ࡜ࡀ᫂






 1-3 ࡣ㸪C4 ఩㸪C5 ఩ࡢ⨨᥮ᵝᘧࡀ␗࡞ࡿࡔࡅ࡛㸪ᵓ㐀ⓗ࡟㠀ᖖ࡟ࡼࡃఝ࡚࠸ࡿ
(Scheme 1)ࠋࡑࡢࡓࡵ㸪๓㥑య࡜ࡋ࡚㸪㐃⥆ࡍࡿ୙ᩧ୰ᚰ࡜ࣅࢽࣝᮎ➃ࢆᣢࡘ࢔࣑ࣀ
࢔ࣝࢥ࣮ࣝ 5-7 ࢆタᐃࡋࡓࠋࡍ࡞ࢃࡕ㸪1-3 ࡣ㸪࢔࣑ࣀ࢔ࣝࢥ࣮ࣝ 5-7 ࡜ᩥ⊩᪤▱ࡢ
࢜ࣞࣇ࢕ࣥ 48)࡜ࡢࢡࣟࢫ࣓ࢱࢭࢩࢫ཯ᛂ࡟ࡼࡾྜᡂ࡛ࡁࡿ࡜⪃࠼ࡓࠋX=OH㸪Y=H
ࡢ࢔ࣝࢣࣥ 5 ࠿ࡽࡣ 1 ࡀ㸪X=Y=H ࡢ࢔ࣝࢣࣥ 6 ࠿ࡽࡣ 2 ࡀ㸪X=Y=OH ࡢ࢔ࣝࢣࣥ 7 ࠿
ࡽࡣ 3 ࡀࡑࢀࡒࢀྜᡂ࡛ࡁࡿࠋࡲࡓ㸪࢔ࣝ࢟ࣝഃ㙐ࢆྜᡂ⤊┙࡟ఙ㛗ࡍࡿࡇ࡜࡛㸪Ⅳ
⣲㙐ࡢ㛗ࡉࡸ⨨᥮ᇶࡢ␗࡞ࡿᵝࠎ࡞ഃ㙐ࢆᣢࡘㄏᑟయྜᡂࡀᐜ᫆࡟࡞ࡿ࡜ᮇᚅ࡛ࡁ
ࡿࠋࡑࡋ࡚㸪5-7 ࡣඹ㏻୰㛫య࢔ࣝࢹࣄࢻ 8 ࡬ࡢ࢔ࣜࣝᇶࡢᑟධ࡟ࡼࡗ࡚ྜᡂࡍࡿࡇ
࡜࡜ࡋࡓࠋᮏྜᡂィ⏬࡛ࡣ㸪ࡇࢀࡽࡢኳ↛≀ࢆඹ㏻ࡍࡿ୰㛫య࠿ࡽྜᡂࡍࡿࡓࡵ㸪
myriocin 㢮ࡢ⥙⨶ⓗ࡞ྜᡂࡀྍ⬟࡜࡞ࡿࠋ㘽࡜࡞ࡿ myriocin 㢮࡟≉ᚩⓗ࡞ C2 ఩ࡢᅄ






 ㏫ྜᡂゎᯒ࡟ᇶ࡙ࡁ㸪ࡣࡌࡵ࡟ Du Bois ࡽࡢᡭἲࢆཧ⪃࡟ ,9) ࢫࣝࣇ࢓࣐࣮ࢺ 12 ࡢ
C-H ࢔࣑ࣀ໬⥆ࡃ࢔ࣝ࢟ࣝ໬࡟ࡘ࠸᳨࡚ウࡋࡓ (Scheme 2)ࠋL-㓇▼㓟ࢪ࢚ࢳࣝ࠿ࡽ 4
ᕤ⛬࡛ᑟ࠸ࡓࢫࣝࣇ࢓࣐࣮ࢺ 12 ࢆ㸪࣮ࣚࢻ࣋ࣥࢮࣥࢪ࢔ࢭࢱ࣮ࢺᏑᅾୗ㸪㓑㓟ࣟࢪ
࣒࢘࡜཯ᛂࡉࡏࡓ࡜ࡇࢁ㸪❧య≉␗ⓗ࡟ C-H ࢔࣑ࣀ໬཯ᛂࡀ㐍⾜ࡋ㸪࢜࢟ࢧࢳ࢔ࢪ
ࢼࣥ N,O-࢔ࢭࢱ࣮ࣝ 13 ࡀ༢୍ࡢ⏕ᡂ≀࡜ࡋ࡚ 84㸣ࡢ཰⋡࡛ᚓࡽࢀࡓࠋ⥆࠸࡚㸪13
ࢆሷ໬ள㖄Ꮡᅾୗ㸪ࣅࢽ࣐ࣝࢢࢿࢩ࣒࢘ࣈ࣑ࣟࢻ࡜཯ᛂࡉࡏࡿ࡜㸪ࣅࢽࣝ࢜࢟ࢧࢳ
࢔ࢪࢼࣥ 14 ࡀ༢୍ࡢࢪ࢔ࢫࢸ࣐࣮ࣞ࢜࡜ࡋ࡚㸪཰⋡ 86㸣࡛ᚓࡽࢀࡓࠋ⏕ᡂ≀ࡢ❧య




᳨ウࡋࡓ (Scheme 3)ࠋ14 ࡢࣄࢻࣟ࢟ࢩᇶ࠾ࡼࡧ࢔࣑ࣀᇶࢆࡑࢀࡒࢀಖㆤࡋࡓᚋ㸪17
ࢆࢸࢺࣛࣄࢻࣟࣇࣛࣥ-0.1 M ࣜࣥ㓟⦆⾪ᾮ୰࡛ 50 °C ࡛ຍ⇕ࡋࡓ࡜ࡇࢁ㸪࢜࢟ࢧࢳ࢔
ࢪࢼࣥ⎔ࡢ㛤⿣ࡀ㐍⾜ࡋࡓࡀ㸪ணᮇࡋࡓ࢔ࣝࢥ࣮ࣝ 18’࡛ࡣ࡞ࡃ㸪1,2-࢔ࢭࢳࣝࢩࣇ




࣮ࣝ 19 ࡀᚓࡽࢀࡓࠋ19 ࢆ 3 ẁ㝵࡛┠ⓗࡢ࢔ࣝࢹࣄࢻ 16 ࡬࡜ኚ᥮ࡋࡓࠋ




ⓗ࡟┠ⓗࡢ 3,4-syn ࡢ࣍ࣔ࢔ࣜࣝ࢔ࣝࢥ࣮ࣝ 20 ࢆᚓࡿࡇ࡜࡟ᡂຌࡋࡓࠋ
 ඲❧య୰ᚰࡢᵓ⠏࡟ᡂຌࡋࡓࡢ࡛㸪ḟ࡟ 1 ࡬ࡢኚ᥮ࢆ᳨ウࡋࡓ (Scheme 5)ࠋ20 ࡢ
ࣄࢻࣟ࢟ࢩᇶࢆ࢔ࢭࢳࣝᇶ࡛ಖㆤࡋࡓᚋ㸪➨஧ୡ௦ Grubbs ゐ፹Ꮡᅾୗ㸪ᩥ⊩᪤▱ࡢ
࢔ࣝࢣࣥ 4 ࡜ࡢࢡࣟࢫ࣓ࢱࢭࢩࢫ཯ᛂ࡟௜ࡋ࡚ᮃࡳࡢ࢔ࣝࢣࣥ 21 ࢆᚓࡓࠋ21 ࡢ tert-
ࣈࢳࣝࢪࣇ࢙ࢽࣝࢩࣜࣝᇶࢆ⬺ಖㆤࡋࡓᚋ㸪ᚓࡽࢀࡓ࢔ࣝࢥ࣮ࣝࡢ㓟໬ࢆ⾜࠸㸪࢝
ࣝ࣎ࣥ㓟 22 ࡬࡜ኚ᥮ࡋࡓࠋ᭱ᚋ࡟㸪඲యࡢ⬺ಖㆤࢆ⾜ࡗ࡚㸪myriocin (1)ࡢ඲ྜᡂࢆ
㐩ᡂࡋࡓࠋ10)
3㸬Mycestericin D ࡢ඲ྜᡂ
㏫ྜᡂゎᯒ࡟ᚑ࠸㸪㘽୰㛫య࢔ࣝࢹࣄࢻ 16 ࠿ࡽ C4 ఩࡟ࣄࢻࣟ࢟ࢩᇶࢆᣢࡓ࡞࠸
࢔ࣝࢣࣥ 6 ࡢྜᡂࢆ᳨ウࡋࡓ (Scheme 6)ࠋࡲࡎ㸪16 ࢆ Wittig ཯ᛂ࡟௜ࡋ㸪D,E-୙㣬





㏫ྜᡂゎᯒ࡟ᚑ࠸㸪3,4,5-syn ࢺ࣮ࣜ࢜ࣝࢆ᭷ࡍࡿ࢔ࣝࢣࣥ 7 ࡢྜᡂࢆ᳨ウࡋࡓ
(Scheme 7)ࠋ㘽୰㛫య࢔ࣝࢹࣄࢻ 16 ࠿ࡽᑟ࠸ࡓD,E-୙㣬࿴࢚ࢫࢸࣝ 23 ࢆ N-࣓ࢳࣝࣔ
ࣝ࣍ࣜࣥᏑᅾୗ㸪ᅄ㓟໬࢜ࢫ࣑࣒࢘ (OsO4)࡜཯ᛂࡉࡏࡓ࡜ࡇࢁ㸪3,4-anti ࢪ࣮࢜ࣝ
26 ࡀ㧗཰⋡㸪㧗❧య㑅ᢥⓗ࡟ᚓࡽࢀࡓࡀ㸪┠ⓗࡢ 3,4-syn యࡣ඲ࡃᚓࡽࢀ࡞࠿ࡗࡓࠋ
ࡑࡇ࡛㸪✀ࠎ᮲௳ࢆ᳨ウࡋࡓ⤖ᯝ㸪23 ࠿ࡽᑟ࠸ࡓ࢔ࣜࣝ࢔ࣝࢥ࣮ࣝ 27 ࢆ N,N,N',N'-
ࢸࢺ࣓ࣛࢳ࢚ࣝࢳࣞࣥࢪ࢔࣑ࣥᏑᅾୗ㸪OsO4࡜཯ᛂࡉࡏࡓ᫬࡟ࢪ࢔ࢫࢸࣞ࢜㑅ᢥᛶ
ࡀ 1㸸1.3 ࡲ࡛ྥୖࡋ㸪┠ⓗࡢ 3,4-syn ࢪ࣮࢜ࣝ 28 ࢆᚓࡿࡇ࡜ࡀ࡛ࡁࡓࠋḟ࡟㸪28 ࢆ
┠ⓗࡢ࢔ࣝࢣࣥ 29 ࡬࡜ኚ᥮ࡋࡓࠋࡑࡋ࡚㸪1 ࡢྜᡂ࡜ྠᵝ࡟㸪4 ࡜ࡢࢡࣟࢫ࣓ࢱࢭ
ࢩࢫ཯ᛂ࡟௜ࡋ㸪ഃ㙐ࡢఙ㛗ࢆ⾜ࡗ࡚㸪sphingofungin E (3)ࡢ඲ྜᡂࢆ㐩ᡂࡋࡓࠋ୍
᪉㸪3,4-anti ࢪ࣮࢜ࣝ 26 ࠿ࡽࡣ㸪3 ࡢྜᡂ࡜ྠᵝࡢᡭἲ࡟ࡼࡾ㸪4,5-di-epi-sphingofungin 
E (3’)ࢆྜᡂࡋࡓࠋ
⤖ㄽ
 ⴭ⪅ࡣ㸪ᕷ㈍ࡢ L-㓇▼㓟ࢪ࢚ࢳࣝ࠿ࡽᑟ࠸ࡓࢫࣝࣇ࢓࣐࣮ࢺ 12 ࡢ Rh(II)ゐ፹ C-H
࢔࣑ࣀ໬⥆ࡃ࢔ࣝ࢟ࣝ໬࡟ࡼࡗ࡚㸪myriocin 㢮࡟≉ᚩⓗ࡞ C2 ఩ࡢᅄ⨨᥮୙ᩧⅣ⣲ࡢ
❧య㑅ᢥⓗ࡞ᵓ⠏࡟ᡂຌࡋࡓࠋࡲࡓ㸪ᚓࡽࢀࡓࣅࢽࣝ࢜࢟ࢧࢳ࢔ࢪࢼࣥ 14 ࡢࣅࢽࣝ
ᇶࡢࣄࢻࣟ࢟ࢩᇶ࡬ࡢኚ᥮ࢆ⤒࡚㸪ඹ㏻୰㛫య࡛࠶ࡿ࢔ࣝࢹࣄࢻ 16 ࢆྜᡂࡋࡓࠋࡑ
ࡋ࡚㸪16 ࡬ࡢ࢔ࣜࣝᇶࡢᑟධ㸪⥆ࡃ࢜ࣞࣇ࢕ࣥ 4 ࡜ࡢࢡࣟࢫ࣓ࢱࢭࢩࢫ཯ᛂࢆ⏝࠸
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X=OH, Y=H : myriocin (1)
X=Y=H : mycestericin D (2)
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Scheme 7 
